Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | FASN | P49327 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907170 | 0.91 | SCN10A (0.46) | SCN10ALRRK2ABL1DHODHFASN | |
| SCHEMBL15907198 | 0.84 | SCN10A (0.48) | SCN10ADHODHALDH1A1MAPTLMNA | |
| SCHEMBL15907206 | 0.79 | KCNQ3 (0.47) | SCN10AABL1DHODHMAPTLMNA | |
| SCHEMBL15907169 | 0.78 | DHODH (0.47) | SCN10ADHODHALDH1A1MAPTLMNA | |
| SCHEMBL15907293 | 0.76 | DHODH (0.40) | SCN10ALRRK2ABL1DHODHFASN | |
| SCHEMBL15907171 | 0.74 | DHODH (0.48) | SCN10AABL1DHODHMAPTLMNA | |
| SCHEMBL15907230 | 0.73 | MAPT (0.38) | SCN10ADHODHMAPTLMNATP53 | |
| SCHEMBL15907224 | 0.73 | MPL (0.36) | SCN10AABL1DHODHPLAUMAPT | |
| SCHEMBL18323501 | 0.72 | KCNQ3 (0.51) | SCN10ADHODHALDH1A1MAPTTP53 | |
| SCHEMBL15907218 | 0.71 | MTOR (0.43) | SCN10AABL1DHODHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | SCN10A 2019/4885LRRK2 219/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.